DRTB

CHA

Tag: DRTB

Landmark clinical trial redefines multidrug-resistant tuberculosis Treatment options

endTB Clinical Trial Offers Multiple New Shortened Drug Regimens to Treat Adults and Children with Multidrug-Resistant Tuberculosis Paris, France; November 15, 2023 – Clinical trial results presented for the first time today at the Union World Conference on Lung Health...

Read more

Ahead of UN TB High-Level Meeting, US corporations J&J and Cepheid must pledge access to lifesaving TB medicines and tests for everyone in need

TB is curable but remains the world’s leading infectious disease killer 12 September 2023, Geneva/New York – Next week, world leaders meet for the second-ever global tuberculosis (TB) High-Level Meeting at the United Nations (UN) in New York, to endorse...

Read more

MSF calls again on J&J to withdraw or abandon extended patents on lifesaving TB drug as main patent expires in India today, opening door to more affordable generics

MSF calls again on J&J to withdraw or abandon extended patents on lifesaving TB drug as main patent expires in India today, opening door to more affordable generics. Recent deal offering controlled generics access in limited countries does not go...

Read more

From Nhlangano to the Future, MSF’s legacy in Shiselweni region: 5 key facts about MSF in Eswatini

As Médecins Sans Frontières/Doctors Without Borders (MSF) prepares to leave the Shiselweni region after 16 years of work, its project in Nhlangano draws to a close. However, to ensure the continued success of the Shiselweni HIV & tuberculosis (TB) programme,...

Read more

MSF applauds Indian Patent Office’s rejection of Johnson & Johnson’s attempt to extend monopoly on lifesaving TB drug

Mumbai, 23 March 2023 – Today, the 2019 patent challenge by two tuberculosis (TB) survivors, Nandita Venkatesan and Phumeza Tisile, was successful: the Indian Patent Office rejected the US pharmaceutical corporation Johnson & Johnson’s (J&J) attempt to extend its monopoly...

Read more

Urgent need to improve access to TB testing to support rollout of better, safer, shorter treatment for drug-resistant TB

Delhi, 22 March 2023 - Médecins Sans Frontières/Doctors Without Borders (MSF) called on governments and donors today to speed up access to new, shorter, safer and more effective treatments* for drug-resistant tuberculosis (DR-TB), as well as the diagnostic tests needed...

Read more

Between life and living: Patients with drug-resistant tuberculosis (DR-TB) share stories of strength, support and suffering

India has the highest burden of both tuberculosis (TB) and multi-drug resistant tuberculosis (MDR-TB) based on estimates in the WHO Global TB Report 2022. The country accounts for 28 percent of the global TB burden.  In its clinic in Mumbai, MSF...

Read more

Global TB Report 2022: MSF calls for scale up of shorter and safer DR-TB treatments to help save more lives

The World Health Organization (WHO) released today the 2022 edition of its Global Tuberculosis (TB) Report, featuring data on the TB response and trends in 215 countries and areas. Among the alarming trends from 2021, there is an increase in the estimated...

Read more

MSF responds to new WHO guidance recommending vastly shorter, improved and better-tolerated treatment for multi drug-resistant TB

Geneva, 3rd May, 2022 - Médecins Sans Frontières/Doctors Without Borders (MSF) are pleased that, having shared the results of TB PRACTECAL, our clinical trial that found a new, safer and more effective six-month oral treatment regimen for multi drug-resistant tuberculosis (MDR-TB), the World...

Read more
Show Buttons
Share On Facebook
Share On Twitter
Share On Linkedin
Contact us
Hide Buttons